from Reuters: Business News https://ift.tt/2HpbRGq
Wednesday, April 25, 2018
Shire bid marks Takeda's latest - and biggest - push for global status
TOKYO (Reuters) - Takeda Pharmaceutical Co Ltd's $64 billion bid for London-listed rare disease specialist Shire Plc bolsters its credentials as Japan's most outward facing drugs firm, a mould-breaking image that has been more than a decade in the making.
from Reuters: Business News https://ift.tt/2HpbRGq
from Reuters: Business News https://ift.tt/2HpbRGq
Related Posts:
Exclusive: KKR shelves $2 billion sale of Singapore-based Goodpack due to market slump: sources- Banks wary of liquidity extend expensive, shorter-dated credit to GE
- Stocks give up meager gains as virus anxiety prevails
- Dollar supported as investors seek safety in liquidity
- U.S. Treasury to tap Wall Street advisory firms on airline aid: WSJ
0 comments:
Post a Comment